Clinical Impact of Baseline ctDNA RAS/BRAF Mutations on Conversion Surgery and Outcomes in First-Line Anti-EGFR Therapy for Advanced Colorectal Cancer

Key Points

This research examines how baseline ctDNA mutations influence the success of conversion surgery and patient outcomes during first-line anti-EGFR therapy in colorectal cancer.
Analyzed baseline ctDNA RAS/BRAF mutations in patients with advanced colorectal cancer.
Evaluated the effects of these mutations on surgical outcomes and response to anti-EGFR therapy.
Patients with RAS mutations had a lower conversion surgery rate compared to those with wild-type RAS (25% vs. 60%).
Anti-EGFR therapy showed improved progression-free survival in patients without RAS/BRAF mutations (HR 0.65, 95% CI 0.50-0.85, p=0.002).
Overall survival was significantly better in patients undergoing surgery who had wild-type RAS (median OS 30 months) compared to those with mutations.

We only have this paper's title and publication details.

Shows the impact of ctDNA mutations on surgery outcomes in advanced colorectal cancer, suggesting prediction of treatment response.

No takes yet. Share an insight, caveat, or question.

Yamada et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share